BioSpace

Sanofi pays Regeneron $1B upfront to continue search for Dupixent successor

Sanofi and Regeneron have had a long and “sometimes contentious” partnership, BMO Capital Markets noted, as the companies contend with the looming loss of exclusivity of their blockbuster drug Dupixent.

Por BioSpace

1 minuto de lectura
Compartir
Sanofi pays Regeneron $1B upfront to continue search for Dupixent successor
Sanofi pays Regeneron $1B upfront to continue search for Dupixent successor

¿Tiene noticias que compartir con el sector de eventos?

Envíe un comunicado de prensa o una noticia y llegue a miles de profesionales del sector de eventos.

Contáctenos→

Más en Health Tech

Perspectivas relacionadas